Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low Dose Tadalafil for Female Overactive Bladder
NCT04500860Phase 1Completed
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Dec 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of tadalafil in overactive bladder syndrome (OAB) (3 arms), sponsored by Kasr Al Ainy Hospital. Primary endpoint: Overactive Bladder Symptoms Score at 6 months. Started Dec 2020; status: completed.
02
Drugs
tadalafil
03
Conditions
overactive bladder syndrome (OAB)
Beyond the preview
Go deeper on NCT04500860.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04500860.